Harvard Bioscience, Inc. (HBIO) Stock Price & Analysis
Harvard Bioscience, Inc. (HBIO) closed at USD 8.31 on Thursday, October 15, 2026, up 1.96% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 8.15; the Oct 15, 2026 session ranged USD 7.95–8.4 on volume of 16,559 shares. Market capitalization is $37.83M, with a 52-week range of USD 3.8–9.4 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/HBIO.md
Key facts (HBIO)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 7.5 (range 7.5–7.5).
- Total return with dividends: 1Y +107.8% vs S&P 500 +18.1%; 5Y -87.8% vs S&P 500 +85.1%.
- Next earnings: 2026-11-10, EPS estimate USD -0.17, revenue estimate $21.8M.
Analysts (HBIO)
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 7.5 (low 7.5, high 7.5).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-12 | Benchmark | Target raised | Speculative Buy | $6 → $7.5 |
Total return (dividends reinvested) (HBIO)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +107.8% | -87.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +108.3% | -34.3% |
| Volatility (annualized) | 85.9% | 68.9% |
| Max drawdown | -45.4% (Dec 2025→Apr 2026) | -96.1% (Nov 2021→May 2025) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 8.31 |
|---|---|
| Change | ▲ 1.96% (up) |
| Previous Close | USD 8.15 |
| Open | USD 8.21 |
| Day Range | USD 7.95 – 8.4 |
| 52-Week Range | USD 3.8 – 9.4 |
| Volume | 16,559 shares |
| Market Cap | $37.83M |
| Exchange | NCM |
Technical Analysis (HBIO)
Nexqual's technical model rates HBIO "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.11 (neutral) |
| vs SMA50 | Above (USD 7.73) |
| MACD | 0.15 (positive) |
Analyst Ratings (HBIO)
Wall Street analysts rate HBIO "Buy" based on 2 analysts, with a mean price target of USD 7.5 (range USD 7.5–7.5), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 7.5 |
| High Target | USD 7.5 |
| Low Target | USD 7.5 |
| Buy / Hold / Sell | 1 / 1 / 0 |
Earnings (HBIO)
| Next Earnings Date | 2026-11-10 |
|---|---|
| EPS Estimate | USD -0.17 |
| Revenue Estimate | $21.80M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.14 vs est -0.21 ▲ beat |
| 2025-12-31 | USD 0 vs est 0.35 ▼ miss |
| 2025-09-30 | USD 0 vs est 0.05 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (HBIO)
| Total Revenue | $87.81M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +11.10% |
| Gross Margin | +58.16% |
| Operating Margin | -2.90% |
| Profit Margin | -11.86% |
| ROE | -89.95% |
| Debt / Equity | 5.96 |
| Current Ratio | 1.87 |
| Total Cash | $6.50M |
| Total Debt | $44.21M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (HBIO)
Nexqual rates Harvard Bioscience, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Weak — Revenue -8% YoY (annual), declining |
|---|---|
| Profitability | Mixed — Gross margin 58%, operating -3% |
| Balance Sheet | Critical — $7M cash vs $44M debt |
| Cash Flow | Solid — Operating cash flow $651K (TTM) |
| Efficiency | Critical — ROE -90%, ROA 1.6% |
Ownership (HBIO)
| Insider Ownership | +9.40% |
|---|---|
| Institutional Ownership | +41.91% |
| Shares Outstanding | 4.55M |
| Float | 3.67M |
| Short % of Float | +1.00% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (HBIO)
Harvard Bioscience, Inc. is led by John Duke (age 54), President, CEO, Director & Member of Scientific Advisory Board, per Nexqual as of October 16, 2026 at 05:22 UTC.
| President, CEO, Director & Member of Scientific Advisory Board | John Duke (age 54) |
|---|---|
| CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer | Mark T. Frost (age 62) |
| Vice President of Global People Operations | Lori Packer |
| Senior Vice President of Commercial | David Panzarella |
| Director of Corporate Accounting & SEC Reporting | David Sirois |
Major Backers & Investors (HBIO)
Notable institutional backers of Harvard Bioscience, Inc. include Weber Capital Management LLC /ADV, Meros Investment Management, Lp, Acadian Asset Management. LLC, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Weber Capital Management LLC /ADV | 6.83% |
| Meros Investment Management, Lp | 4.02% |
| Acadian Asset Management. LLC | 3.95% |
| Nano Cap New Millennium Growth Fund L P | 3.14% |
| Corsair Capital Management, L.P. | 2.7% |
| Two Sigma Investments, LP | 2.52% |
| Renaissance Technologies | 2.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.45% |
| BlackRock | 1.36% |
| Geode Capital | 1.04% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KMTS | Kestra Medical Technologies, Lt | USD 28.68 | ▲ 6.34% |
| XRAY | DENTSPLY SIRONA Inc. | USD 8.83 | ▲ 3.76% |
| LMAT | LeMaitre Vascular, Inc. | USD 83.16 | ▲ 1.97% |
| ATRC | AtriCure, Inc. | USD 57.78 | ▲ 1.6% |
| WRBY | Warby Parker Inc. | USD 24.59 | ▼ 7.28% |
| PLSE | Pulse Biosciences, Inc | USD 45.59 | ▼ 6.08% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt